MaaT Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 4RD?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	268,133	1.6%
Private Companies	4,789,527	28.6%
VC/PE Firms	5,166,304	30.9%
Institutions	6,519,847	38.9%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.9%.

Top Shareholders

Top 11 shareholders own 104.1% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
38.6%	Natixis Investment Managers	6,208,490	€30.4m	136%	1.72%
17.7%	BIOCODEX - Incubação de Empresas de Ciências da Vida, S.A.	2,842,792	€13.9m	130%	no data
17.4%	Bpifrance Participations SA	2,802,439	€13.7m	0%	0.12%
12.1%	Symbiosis LLC	1,946,735	€9.5m	-3.99%	no data
8.78%	Crédit Mutuel Innovation	1,412,364	€6.9m	0%	100.0%
5.92%	Artal Group S.A.	951,501	€4.7m	0%	0.2%
1.65%	Herve Affagard	266,173	€1.3m	13.9%	no data
1.03%	Propel Bio Management, LLC	166,423	€815.5k	0%	1.17%
0.87%	Simplify Asset Management Inc.	139,772	€684.9k	-16%	0.03%
0.032%	Financiere Arbevel	5,162	€25.3k	0%	no data
0.012%	Karim Dabbagh	1,960	€9.6k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/23 13:07
End of Day Share Price	2025/05/23 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MaaT Pharma SA is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Stephanie Lefebvre	Gilbert Dupont
Emmanuel Parot	Gilbert Dupont
Vernon Bernardino	H.C. Wainwright & Co.